Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGDS | O60760 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1052812 | 0.86 | NPC1 (0.74) | LMNANPC1SMYD3ALDH1A1HDAC6 | |
| SCHEMBL10268218 | 0.84 | NPC1 (0.71) | LMNANPC1SMYD3ALDH1A1HDAC6 | |
| SCHEMBL112036 | 0.83 | NPC1 (0.69) | LMNANPC1SMYD3ALDH1A1HDAC6 | |
| SCHEMBL3984997 | 0.82 | NPC1 (0.79) | LMNANPC1SMYD3ALDH1A1HDAC6 | |
| SCHEMBL1052303 | 0.82 | NPC1 (0.68) | LMNANPC1SMYD3ALDH1A1HDAC6 | |
| SCHEMBL30265317 | 0.81 | NPC1 (0.81) | LMNANPC1SMYD3ALDH1A1HDAC6 | |
| SCHEMBL32670686 | 0.80 | NPC1 (0.65) | LMNANPC1SMYD3ALDH1A1HDAC6 | |
| SCHEMBL19710135 | 0.79 | NPC1 (0.78) | LMNANPC1SMYD3ALDH1A1HDAC6 | |
| SCHEMBL21489973 | 0.79 | NPC1 (0.78) | LMNANPC1SMYD3ALDH1A1HDAC6 | |
| Hydrochloric Acid SCHEMBL30265370 | 0.79 | NPC1 (0.74) | LMNANPC1SMYD3HDAC6NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | VTV THERAPEUTICS LLC (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | HBB, HBZ, HBG1 | LMNA 973/4885NPC1 868/4885SMYD3 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.